The sale is small relative to market cap and conducted under a pre-arranged 10b5-1 plan, reducing the likelihood of opportunistic insider selling. Monitor the company's upcoming earnings and any changes in insider trading patterns for further signals.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $56.18entry
- T+1 · 6d ago +4.18%α +2.86% · $58.53
- T+4 · todayOpen
- T+5 · in 8h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director B. Lynne Parshall filed a Form 144 notice of intent to sell 5,000 shares of Cytokinetics common stock, with an estimated aggregate market value of $268,450. The shares were acquired via restricted stock units vested on May 14, 2026. The sale is planned for execution on or after November 9, 2026, and is part of a 10b5-1 trading plan established on September 1, 2026.
Key Facts
- Director B. Lynne Parshall intends to sell 5,000 shares of common stock.
- Estimated aggregate market value of the proposed sale is $268,450.
- Shares were acquired via restricted stock units that vested on May 14, 2026.
- The sale is planned for execution on or after November 9, 2026.
- The sale is conducted under a 10b5-1 trading plan established on September 1, 2026.
- The filing is an advance notice of intent to sell, not a completed transaction.
Financial Impact
Proposed sale of 5,000 shares valued at approximately $268,450, representing about 0.0036% of the company's $7.7B market cap.
Risk Factors
- The sale may not be completed; Form 144 is only an intent to sell.
- Director-level sales, even small ones, can sometimes signal reduced conviction, though the 10b5-1 plan mitigates this concern.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010860 |
| Document: 0001950047-26-010860-index.html | 0001950047-26-010860 |
| Document: 0001950047-26-010860.txt | 0001950047-26-010860 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Viewing Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers